Xencor Inc
NASDAQ:XNCR

  • LAST PRICE
    23.3100
  • TODAY'S CHANGE (%)
    -0.3100 (-1.3124%)
  • Bid / Lots
    23.1000/ 5
  • Ask / Lots
    23.8500/ 5
  • Open / Previous Close
    23.7700 / 23.6200
  • Day Range
    23.2500
    24.0900
  • 52 Week Range
    15.3100
    26.8400
  • Volume
    649,044

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
XNCR
Xencor Inc
1.7B
-7.3x
---
TVTX
Travere Therapeutics Inc
1.5B
-4.2x
---
RCUS
Arcus Biosciences Inc
1.6B
-5.6x
---
DVAX
Dynavax Technologies Corp
1.7B
135.1x
---
MIRM
Mirum Pharmaceuticals Inc
2.0B
-17.3x
---
AUPH
Aurinia Pharmaceuticals Inc
1.2B
-24.2x
---
As of 2024-11-11

Company Information

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Contact Information

Headquarters
465 N. HALSTEAD ST., SUITE 200PASADENA, CA, United States 91107
Phone
626-305-5900
Fax
626-305-0350

Executives

President, Chief Executive Officer, Founder and Director
Bassil Dahiyat
Senior Vice President, Chief Financial Officer
Bart Cornelissen
Executive Vice President - Research, Chief Scientific Officer
John Desjarlais
Executive Vice President, Chief Development Officer
Nancy Valente
Senior Vice President, General Counsel, Corporate Secretary
Celia Eckert

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$1.7B
Revenue (TTM)
$85.2M
Shares Outstanding
70.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.66
EPS
$-3.20
Book Value
$10.96
P/E Ratio
-7.3x
Price/Sales (TTM)
19.4
Price/Cash Flow (TTM)
---
Operating Margin
-279.34%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.